Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linvoseltamab vs Dara-VCd in Newly Diagnosed Systemic Light Chain Amyloidosis
NCT07901725Phase 3Not yet recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Dec 2026
- Primary completion
- Jul 2035
01
Overview
A Phase 3 trial of linvoseltamab in systemic light chain amyloidosis, sponsored by Regeneron Pharmaceuticals. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
linvoseltamab
03
Conditions
systemic light chain amyloidosis
Beyond the preview
Go deeper on NCT07901725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07901725.